Spectrum Science

The frameworks are everywhere. But does any of it actually work? That was the question Ruzanna Martirosyan, Executive Director of Customer Experience & Emerging Technologies, put to the room at the Pharma Omnichannel Excellence Conference — and the answer was refreshingly honest. Her session, "Building Successful Customer Experience Beyond The Buzz", didn't traffic in aspiration. It tackled the operational realities that quietly kill CX progress before it even starts. The big takeaways: 📌 CX architecture must fit the business model, so what works in oncology looks nothing like consumer health or rare disease 📌 The silent killers of omnichannel progress aren't technology gaps, they're fragmented data ownership, misaligned commercial and medical incentives, and field force resistance 📌 Real audience understanding isn't built in a workshop. It's built from HCP input, behavioural data, and field intelligence — and it needs to keep evolving 📌 CX only gets a seat at the table when it's connected to metrics leadership and finance actually care about The conversation doesn't stop here. Ruzanna has gone deeper on how AI is reshaping pharma omnichannel strategy and where most organisations are still getting it wrong. 👉 Read her latest thinking here: https://lnkd.in/gJmE4xnU #PharmaOmnichannel #MomentumGuaranteed #SpectrumScience #HealthcareComms #CX

What a wonderful day celebrating the #MMMWomenofDistinction in NYC yesterday! ✨ A special congratulations to our own Amy Swissler Hutnik and Jenn Melendez. We couldn't be prouder to see your leadership and contributions recognized among such an outstanding group of honorees. Here's to the women driving meaningful change and shaping what's next!

#ASCO2026 made one thing clear: oncology momentum is building quickly. From precision medicine to immunotherapy and platform therapeutics, the signals coming out of this year’s meeting point to a field evolving fast. Read the full blog from Maia Arnold, PhD, MBA on Spectrum Science’s take: https://lnkd.in/gB5EN6fg

As #ASCO2026 enters its final stretch, the tone shifts—from headline-making datasets to deeper conversations about what it all means in practice. Day 4 is where the field starts to translate momentum into meaning—and several themes are coming into sharper focus: 💡 From signal to strategy Beyond topline results, discussions are centering on how to interpret variability across subgroups, sequencing decisions, and what these data mean for everyday clinical practice. 💡 Refining patient selection The complexity of biomarker-driven care continues to grow. Today’s conversations emphasize not just who benefits, but how precisely we can identify those patients—and how to adapt when biology evolves. 💡 Managing resistance, not just response A recurring theme is the inevitability of resistance—and the need for smarter strategies to anticipate, delay, and overcome it through rational combinations and sequencing. 💡 Clinical nuance matters more than ever As options expand, differentiation is increasingly defined by context—line of therapy, prior exposure, molecular profile, and tolerability. The “right therapy” is becoming more situational and more personalized. 💡 Operationalizing innovation There is growing attention on what it takes to bring these advances into the real world—testing infrastructure, access to biomarker-driven care, and the practical realities of delivering complex regimens.   The question is no longer just what works—but for whom, when, and how to use it most effectively. As the meeting concludes, the focus turns to implementation—how the field translates a rapidly expanding evidence base into clear, confident clinical decision-making.

Omnichannel. AI. CX transformation. The frameworks are everywhere, but how many actually survive contact with reality? Ruzanna Martirosyan is taking the stage at the Pharma Omnichannel Excellence Conference in London on 3rd June to find out. Her session, “Building Successful Customer Experience Beyond The Buzz” doesn't just name the problem. It tackles the real barriers killing CX progress: fragmented data, misaligned incentives, and strategies that look great in a deck but collapse in execution. Catch her on stage at 12.00 and if you want to keep the conversation going, Chris Bath is also attending and very happy to connect. #PharmaOmnichannel #MomentumGuaranteed #SpectrumScience

Everyone is talking about AI in pharma but fewer are talking about how to apply it in ways that are actually useful, scalable, and compliant. In this new blog, Ruzanna Martirosyan breaks down where AI is creating real omnichannel value today and why strong data, governance, and human oversight still matter. Read the full blog: https://lnkd.in/gJmE4xnU

Hear Maia Arnold, PhD, MBA's take on Day 3 at #ASCO2026 and a quick written recap below on defining what comes next in oncology. As we move through Day 3, a clear picture is continuing to take shape—one that reflects not just progress, but a fundamental shift in how we approach cancer care. Across today’s sessions, several themes stand out: 🌟 Moving earlier, moving smarter: Therapies traditionally reserved for later lines are being brought forward, with the goal of improving long-term outcomes—and increasingly, cure. 🌟 Combination strategies maturing: Innovation is no longer just about new agents, but how we rationally combine IO, targeted therapies, and novel modalities to overcome resistance. 🌟 Precision, redefined: Biomarkers are evolving from static selection tools to dynamic guides for treatment decisions over time. 🌟 Durability as a differentiator: Depth and durability of response are emerging as critical measures of clinical value in an increasingly crowded landscape. The plenary session further underscores these shifts, with data that begin to reshape expectations around what is achievable in earlier lines of therapy and in molecularly defined populations. We’ll share more as the full implications come into focus. We’re also seeing continued momentum behind next-generation approaches, including today’s data from Revolution Medicines, reinforcing a critical inflection point for the field. The call to science is becoming clearer: We are moving beyond nonspecific approaches that broadly target dividing cells. The opportunity now is to directly target the drivers of cancer—with greater precision, greater intent, and the potential for more meaningful, durable outcomes. The time is now.

Another full day of compelling data and forward momentum across oncology at #ASCO26. Clear themes continue to emerge from our team on the ground: ✅ Earlier intervention is redefining the treatment paradigm with more therapies moving into frontline and even curative-intent settings ✅ Combination approaches—anchored in immuno-oncology—are now the foundation of care, with next-generation strategies (including bispecifics) pushing efficacy further ✅ Precision oncology is becoming more dynamic, driven by biomarkers, real-time profiling, and AI-enabled insights to better match patients to the right therapies ✅ Novel modalities are expanding the playbook, from ADCs to bispecifics, broadening what is considered “targetable” disease Now, all eyes turn to tomorrow’s plenary—anticipating key updates on RAS(ON) inhibition and overall survival data with VEGF/PD-1 combinations. These readouts will be critical in defining where the next wave of innovation meaningfully shifts standards of care. Amid the scientific excitement, ASCO remains a powerful reminder of why this work matters. Clinical trials are here to serve patients and not the other way around. The pace of innovation reflects an industry deeply committed to delivering not just progress, but meaningful impact for the people who need it most.

Excited to kick off Day 1 at #ASCO! Spectrumites Maia Arnold, PhD, MBA, Melissa Malrechauffe and Jaryd Leady are on the ground and looking forward to a week of impactful science, meaningful dialogue, and bringing you the latest insights from the oncology community. Are you here, too? What are you most excited about?!

ENDO 2026 feels like a turning point for endocrinology. From Spectrum Science’s perspective, the story goes beyond scale in obesity and metabolic disease to emerging momentum in rare disease and early signals of disease modification. This is where scientific progress and commercial opportunity begin to converge. Read Shay Ashline, PhD, MBA's take to see what’s next: https://lnkd.in/gi2QtUMa